Regeneron Pharmaceuticals Finance Lease Liabilities decreased by 100.0% to $0.00 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $720.00M to $0.00. Over 5 years (FY 2020 to FY 2025), Finance Lease Liabilities shows relatively stable performance with a 0.1% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Higher levels increase the company's long-term leverage and fixed-cost base, while lower levels indicate a more equity-funded or asset-light approach.
The long-term portion of obligations for leases that are classified as financing arrangements, typically involving the e...
Analyzed alongside long-term debt to determine the total contractual leverage and solvency risk of the business.
finance_lease_liabilities| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $720.00M | $720.00M | $720.00M | $720.00M | $720.00M | $720.00M | $720.00M | $720.00M | $720.00M | $720.00M | $720.00M | $720.00M | $720.00M | $720.00M | $720.00M | $720.00M | $0.00 |
| QoQ Change | — | — | — | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | -100.0% |
| YoY Change | — | — | — | — | — | — | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | -100.0% |